CMM6
MCID: MLN051
MIFTS: 23

Melanoma, Cutaneous Malignant, 6 (CMM6) malady

Categories: Genetic diseases, Skin diseases, Rare diseases, Nephrological diseases, Cancer diseases

Aliases & Classifications for Melanoma, Cutaneous Malignant, 6

Aliases & Descriptions for Melanoma, Cutaneous Malignant, 6:

Name: Melanoma, Cutaneous Malignant, 6 54 24 13
Cutaneous Malignant Melanoma 6 66 29
Cmm6 24 66
Melanoma, Cutaneous Malignant 6 66

Classifications:



External Ids:

OMIM 54 613972
MedGen 40 C3151417
MeSH 42 D008545

Summaries for Melanoma, Cutaneous Malignant, 6

OMIM : 54 Malignant melanoma is a neoplasm of pigment-producing cells called melanocytes that occurs most often in the skin, but... (613972) more...

MalaCards based summary : Melanoma, Cutaneous Malignant, 6, also known as cutaneous malignant melanoma 6, is related to malignant melanoma, somatic. An important gene associated with Melanoma, Cutaneous Malignant, 6 is XRCC3 (X-Ray Repair Cross Complementing 3). The drugs Fentanyl and Dabrafenib have been mentioned in the context of this disorder. Affiliated tissues include skin and eye.

UniProtKB/Swiss-Prot : 66 Melanoma, cutaneous malignant 6: A malignant neoplasm of melanocytes, arising de novo or from a pre- existing benign nevus, which occurs most often in the skin but also may involve other sites.

Related Diseases for Melanoma, Cutaneous Malignant, 6

Diseases in the Melanoma, Cutaneous Malignant 8 family:

Melanoma, Cutaneous Malignant, 9 Melanoma, Cutaneous Malignant 10
Melanoma, Cutaneous Malignant, 2 Melanoma, Cutaneous Malignant, 3
Melanoma, Cutaneous Malignant, 6 Melanoma, Cutaneous Malignant, 5
Cdk4-Related Cutaneous Malignant Melanoma Cdkn2a-Related Cutaneous Malignant Melanoma
Pot1-Related Susceptibility to Cutaneous Malignant Melanoma

Diseases related to Melanoma, Cutaneous Malignant, 6 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 malignant melanoma, somatic 10.9

Symptoms & Phenotypes for Melanoma, Cutaneous Malignant, 6

Clinical features from OMIM:

613972

Drugs & Therapeutics for Melanoma, Cutaneous Malignant, 6

Drugs for Melanoma, Cutaneous Malignant, 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Dabrafenib Approved Phase 3 44462760 44516822
3
nivolumab Approved Phase 3,Phase 1,Phase 2 946414-94-4
4
Trametinib Approved Phase 3,Phase 1 871700-17-3 11707110
5
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
6 Adjuvants, Anesthesia Phase 3
7 Analgesics Phase 3,Phase 2
8 Analgesics, Opioid Phase 3
9 Anesthetics Phase 3
10 Anesthetics, General Phase 3
11 Anesthetics, Intravenous Phase 3
12 Central Nervous System Depressants Phase 3
13 Liver Extracts Phase 3
14 Narcotics Phase 3
15 pancreatic polypeptide Phase 3
16 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
17 Antibodies Phase 3,Phase 2,Phase 1
18 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
19 Immunoglobulins Phase 3,Phase 2,Phase 1
20 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
21 Anti-Infective Agents Phase 3,Phase 2
22 Antiviral Agents Phase 3,Phase 2
23 Interferon-alpha Phase 3,Phase 2
24 interferons Phase 3,Phase 2,Phase 1
25 Cola Nutraceutical Phase 3
26
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
27
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
28
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
29
Dacarbazine Approved, Investigational Phase 1, Phase 2 4342-03-4 5351166
30
Succinylcholine Approved Phase 1, Phase 2 306-40-1 5314
31
Vinblastine Approved Phase 1, Phase 2 865-21-4 13342 241903
32
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
33
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
34
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
35
Vidarabine Approved Phase 2 24356-66-9 32326 21704
36
Nintedanib Approved Phase 1, Phase 2 656247-17-5 56843413
37
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
38
Trabectedin Approved, Investigational Phase 1, Phase 2 114899-77-3 108150
39
Progesterone Approved, Vet_approved Phase 1, Phase 2 57-83-0 5994
40
Benzocaine Approved Phase 2 1994-09-7, 94-09-7 2337
41
Metformin Approved Phase 2 657-24-9 14219 4091
42
Acitretin Approved Phase 2 55079-83-9 6437841 5284513
43 tannic acid Approved, Nutraceutical Phase 2
44
Vatalanib Investigational Phase 2 212141-54-3 151194
45 Alkylating Agents Phase 2,Phase 1
46 Antineoplastic Agents, Alkylating Phase 2,Phase 1
47 Antimitotic Agents Phase 1, Phase 2
48 Antineoplastic Agents, Phytogenic Phase 1, Phase 2
49 Neuromuscular Agents Phase 1, Phase 2
50 Neuromuscular Blocking Agents Phase 1, Phase 2

Interventional clinical trials:

(show all 42)
id Name Status NCT ID Phase
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
2 Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Recruiting NCT02224781 Phase 3
3 High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Recruiting NCT02506153 Phase 3
4 Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. Unknown status NCT01168050 Phase 2
5 A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread Completed NCT01395121 Phase 2
6 Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery Completed NCT00563823 Phase 2
7 Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma Completed NCT00539591 Phase 2
8 Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma Completed NCT01196416 Phase 1, Phase 2
9 Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer Completed NCT00328861 Phase 2
10 Trial of pIL-12 Electroporation Malignant Melanoma Completed NCT01502293 Phase 2
11 Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma Completed NCT01435369 Phase 2
12 Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma Recruiting NCT02308553 Phase 1, Phase 2
13 Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Stu Recruiting NCT01973322 Phase 2
14 A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors Recruiting NCT02819843 Phase 2
15 Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Recruiting NCT03021460 Phase 2
16 Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma Recruiting NCT03138161 Phase 1, Phase 2
17 Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Recruiting NCT02779855 Phase 1, Phase 2
18 Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma Recruiting NCT01807182 Phase 2
19 RTA 408 Capsules in Patients With Melanoma - REVEAL Recruiting NCT02259231 Phase 1, Phase 2
20 Survivorship Promotion In Reducing IGF-1 Trial Active, not recruiting NCT02431676 Phase 2
21 Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma Active, not recruiting NCT01827111 Phase 2
22 A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma Terminated NCT02050321 Phase 2
23 Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Completed NCT01131234 Phase 1
24 Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery Completed NCT01989559 Phase 1
25 Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma Completed NCT01264731 Phase 1
26 Clinical Study of CMP-001 in Combination With Pembrolizumab Recruiting NCT02680184 Phase 1
27 A Study of Subcutaneous Recombinant Human hetIL-15 (IL15/sIL-15Ra) in Adults With Metastatic Cancers Recruiting NCT02452268 Phase 1
28 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Recruiting NCT02020707 Phase 1
29 Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Recruiting NCT02858869 Phase 1
30 Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies Active, not recruiting NCT01364051 Phase 1
31 Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients Active, not recruiting NCT02437279 Phase 1
32 Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer Active, not recruiting NCT01727076 Phase 1
33 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors Terminated NCT02065063 Phase 1
34 Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated NCT02346955 Phase 1
35 Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma Completed NCT00597272
36 Tailored Intervention for Melanoma Patient's Families Completed NCT00816374
37 Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy Recruiting NCT02857374
38 Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners Recruiting NCT03112668
39 A Randomized Trial to Assess the Role of Imaging During Follow up After Radical Surgery of High Risk Melanoma Not yet recruiting NCT03116412
40 Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma Terminated NCT00996827
41 Impact of Obstructive SAS on Metastatic Potential of Cutaneous Melanoma Withdrawn NCT02699918 Early Phase 1
42 Mohs and Immunofluorescence for Malignant Melanoma In Situ Withdrawn NCT02306512

Search NIH Clinical Center for Melanoma, Cutaneous Malignant, 6

Genetic Tests for Melanoma, Cutaneous Malignant, 6

Genetic tests related to Melanoma, Cutaneous Malignant, 6:

id Genetic test Affiliating Genes
1 Cutaneous Malignant Melanoma 6 29
2 Melanoma, Cutaneous Malignant, 6 24 XRCC3

Anatomical Context for Melanoma, Cutaneous Malignant, 6

MalaCards organs/tissues related to Melanoma, Cutaneous Malignant, 6:

39
Skin, Eye

Publications for Melanoma, Cutaneous Malignant, 6

Variations for Melanoma, Cutaneous Malignant, 6

UniProtKB/Swiss-Prot genetic disease variations for Melanoma, Cutaneous Malignant, 6:

66
id Symbol AA change Variation ID SNP ID
1 XRCC3 p.Thr241Met VAR_013006 rs861539

ClinVar genetic disease variations for Melanoma, Cutaneous Malignant, 6:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 XRCC3 NM_001100119.1(XRCC3): c.722C> T (p.Thr241Met) single nucleotide variant risk factor rs861539 GRCh37 Chromosome 14, 104165753: 104165753

Cosmic variations for Melanoma, Cutaneous Malignant, 6:

9 (show all 14)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM580 NRAS skin,ear,malignant melanoma,NS c.181C>A p.Q61K 5
2 COSM5049808 NF1 skin,ear,malignant melanoma,NS c.3652C>T p.Q1218* 5
3 COSM5049807 NF1 skin,ear,malignant melanoma,NS c.3097C>T p.Q1033* 5
4 COSM1651647 KIT skin,eye,malignant melanoma,NS c.1459G>A p.G487S 5
5 COSM110485 GRIN2A skin,ear,malignant melanoma,NS c.3217G>A p.E1073K 5
6 COSM109660 GRIN2A skin,ear,malignant melanoma,NS c.4097C>T p.P1366L 5
7 COSM106626 GRIN2A skin,ear,malignant melanoma,NS c.1959G>A p.M653I 5
8 COSM141892 CNR1 skin,ear,malignant melanoma,NS c.145C>T p.P49S 5
9 COSM141856 CHRM3 skin,ear,malignant melanoma,NS c.1741T>A p.F581I 5
10 COSM1125 BRAF skin,ear,malignant melanoma,NS c.1790T>A p.L597Q 5
11 COSM476 BRAF skin,ear,malignant melanoma,NS c.1799T>A p.V600E 5
12 COSM27639 BRAF skin,ear,malignant melanoma,NS c.1780G>A p.D594N 5
13 COSM478 BRAF skin,ear,malignant melanoma,NS c.1801A>G p.K601E 5
14 COSM471 BRAF skin,ear,malignant melanoma,NS c.1790T>G p.L597R 5

Expression for Melanoma, Cutaneous Malignant, 6

Search GEO for disease gene expression data for Melanoma, Cutaneous Malignant, 6.

Pathways for Melanoma, Cutaneous Malignant, 6

GO Terms for Melanoma, Cutaneous Malignant, 6

Sources for Melanoma, Cutaneous Malignant, 6

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....